Market capitalization | $27.27m |
Enterprise Value | $3.42m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.03 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-16.15m |
Free Cash Flow (TTM) Free Cash Flow | $-13.99m |
Cash position | $24.62m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
2 Analysts have issued a Enlivex Therapeutics Ltd forecast:
2 Analysts have issued a Enlivex Therapeutics Ltd forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.71 -0.71 |
17%
17%
|
|
EBITDA | -15 -15 |
24%
24%
|
EBIT (Operating Income) EBIT | -16 -16 |
24%
24%
|
Net Profit | -19 -19 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
Head office | Israel |
CEO | Oren Hershkovitz |
Employees | 49 |
Founded | 2012 |
Website | www.enlivex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.